Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA44
|
| gptkbp:blackBoxWarning |
serious meningococcal infections
|
| gptkbp:CASNumber |
1448221-90-9
|
| gptkbp:contraindication |
Neisseria meningitidis infection
|
| gptkbp:developedBy |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:form |
solution for infusion
|
| gptkbp:genericName |
gptkb:ravulizumab
|
| gptkbp:halfLife |
~49 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ultomiris
|
| gptkbp:indication |
gptkb:paroxysmal_nocturnal_hemoglobinuria
gptkb:atypical_hemolytic_uremic_syndrome |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
complement C5 inhibitor
|
| gptkbp:molecularWeight |
148 kDa
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea diarrhea headache hypertension upper respiratory tract infection |
| gptkbp:bfsParent |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|